Plato Investment Management Ltd Makes New Investment in Edwards Lifesciences Corporation $EW

Plato Investment Management Ltd bought a new position in Edwards Lifesciences Corporation (NYSE:EW) in the 2nd quarter, HoldingsChannel reports. The fund bought 10,083 shares of the medical research company’s stock, valued at approximately $907,000.

Several other large investors also recently made changes to their positions in the company. Hanson & Doremus Investment Management acquired a new position in shares of Edwards Lifesciences during the first quarter worth approximately $25,000. JPL Wealth Management LLC bought a new position in Edwards Lifesciences in the 3rd quarter worth approximately $25,000. MV Capital Management Inc. bought a new position in Edwards Lifesciences in the 4th quarter worth approximately $26,000. RMG Wealth Management LLC acquired a new stake in Edwards Lifesciences in the 1st quarter valued at approximately $26,000. Finally, Kemnay Advisory Services Inc. acquired a new stake in Edwards Lifesciences in the 4th quarter valued at approximately $27,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on EW. Robert W. Baird boosted their price target on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. Royal Bank Of Canada raised their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Monday, July 13th. TD Cowen restated a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Mizuho lifted their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Finally, BTIG Research upped their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $100.27.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $91.13 on Wednesday. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The stock has a market cap of $52.47 billion, a price-to-earnings ratio of 52.37, a PEG ratio of 2.30 and a beta of 0.85. The stock’s 50 day moving average price is $88.90 and its 200 day moving average price is $84.49. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same period last year, the company posted $0.67 EPS. The firm’s quarterly revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president directly owned 98,611 shares in the company, valued at approximately $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 25,570 shares of company stock worth $2,219,390 over the last 90 days. 0.31% of the stock is currently owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.